J. P. Leonard

Articles by J. P. Leonard

Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data

ByJ. P. Leonard,A. D. Zelenetz,J. M. Vose,J. A. Radford,R. L. Wahl,A. Rohatiner,S. Kroll,R. Stagg,K. Nadeau,N. Valente,M. S. Kaminski

March 1st 2001

Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses

Efficacy and Safety of Tositumomab/Iodine-131 Tositumomab in the Expanded Access Study: Interim Report From Two Institutions

ByS. A. Gregory,M. Coleman,A. Ali,T. M. O'Brien,A. Subramanian,L. Kostakoglu,S. J. Goldsmith,N. Valente,J. P. Leonard

March 1st 2001

Relapsed or refractory low-grade non-Hodgkin’s lymphoma (NHL) and transformed low-grade NHL are incurable diseases. Tositumomab/iodine-131 tositumomab (Bexxar) is a novel

J. P. Leonard

Articles by J. P. Leonard

Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data

Efficacy and Safety of Tositumomab/Iodine-131 Tositumomab in the Expanded Access Study: Interim Report From Two Institutions

Latest Updated Articles

Trending on CancerNetwork

Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC

FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma

The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes

Selinexor Combo Improves Spleen Volume Reduction in Myelofibrosis

Exploring the Role of Radiation Oncology in Kidney Cancer Awareness Month